Altimmune (ALT) Corporate presentation summary

Strategic focus and mission

• Aims to revolutionize care for serious liver diseases, targeting MASH, AUD, and ALD with significant unmet needs.

• Pemvidutide, a dual glucagon/GLP-1 agonist, is the lead candidate, designed for direct liver and metabolic effects.

• Robust patent protection extends into the 2040s, supporting long-term commercial potential.

• Strong financial position with $519 million in cash, funding operations through key Phase 3 data readouts.

Clinical pipeline and milestones

• PERFORMA Phase 3 MASH trial initiated in July 2026, with 52-week data expected in 2029.

• Positive topline data from RECLAIM Phase 2 AUD trial and completed enrollment for RESTORE Phase 2 ALD trial in July 2026.

• Pemvidutide holds FDA Fast Track and Breakthrough Therapy designations for MASH and Fast Track for AUD.

MASH (Metabolic Dysfunction-Associated Steatohepatitis) program

• MASH is a progressive liver disease linked to obesity, diabetes, and is a leading cause of liver transplantation.

• Pemvidutide demonstrated rapid, significant reductions in liver fat, inflammation, and fibrosis in Phase 2 trials.

• Maintained >50% liver fat reduction and 7.5% weight loss at 48 weeks with favorable tolerability.

• Showed strong improvements in non-invasive fibrosis markers (ELF, LSM) and competitive efficacy versus other therapies.

• Phase 3 trial includes global enrollment and aims for accelerated and full approval based on biopsy and clinical outcomes.